Working… Menu

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04026841
Recruitment Status : Recruiting
First Posted : July 19, 2019
Last Update Posted : August 2, 2019
Information provided by (Responsible Party):
Jianxing He, The First Affiliated Hospital of Guangzhou Medical University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : February 1, 2020